Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis

Nishijima, Tomohiro F., Muss, Hyman B., Shachar, Shlomit S., Moschos, Stergios J.·2016·Cancer Treatment Reviews
DOI 10.1016/j.ctrv.2016.02.006

Cited by (292)

Items 201–292 of 292

  1. Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types
    Fengyun Zhang, Kaimiao Hu, Changming Sun, Ruibing Chen, Guangjian Ni, Xiaofeng Liu, Leyi Wei, Ran Su · 2026 · Gut Microbes
  2. Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study
    Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, Mario Domenico Rizzato, Anna Lena Saborowski, Lorenzo Antonuzzo, Federico Rossari, Tomoyuki Satake, Frederik Peeters, Caterina Vivaldi et al. · 2025 · International Journal of Cancer
  3. Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
    Yutaka Takahara, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato et al. · 2023 · Thoracic Cancer
  4. Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
    Damir Vučinić, Iva Skočilić, Marin Golčić, Renata Dobrila-Dintinjana, Maja Kolak, Ivona Jerkovic, Eleonora Cini Tešar, Ani Mihaljević Ferari, Arnela Redjovic, Jasna Marušić et al. · 2024 · Journal of Personalized Medicine
  5. Real-World Data on Immune-Checkpoint Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Study
    José del Corral-Morales, Carlos Ayala-de Miguel, Laura Quintana Cortés, Adrián Sanchez-Vegas, Fuensanta Aranda-Bellido, Santiago González-Santiago, José Fuentes, Pablo Ayala-de Miguel · 2025 · Cancers
  6. A Coming of Age for Immune Checkpoint Inhibitors in Cancer
    Ryan David Nipp, Justin F. Gainor · 2019 · Immunotherapy
  7. Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies
    Yaojie Zhou, Chengdi Wang, Yuting Jiang, Pengwei Ren, Jun Shao, Paierhati Tuersun, Weimin Li · 2020 · Biomarkers
  8. Immunotherapy in Special and Rare Situations: A Brief Review
    Sujay Srinivas, Jyoti Bajpai · 2021 · Journal of Immunotherapy and Precision Oncology
  9. The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status
    Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, YooHyun Song, Yoshifumi Hori, Toshihisa Tomoda, Mirii Harada, Shingo Tamura, Hiroki Kobayashi et al. · 2022 · OncoTargets and Therapy
  10. Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy
    Qianqian Hou, Heng Xu · 2020 · Advances in experimental medicine and biology
  11. Immunotherapy in Elderly Patients: Should We Stay or Should We Go?
    Vincenzo Di Nunno, Enrico Franceschi, Alba Ariela Brandes · 2020 · Future Oncology
  12. More than age: Impact of comorbidity and polypharmacy on immune-related adverse events, treatment discontinuation, and toxicity management in older patients receiving immune checkpoint inhibitors
    Anja Gesierich, Eran Demeter, Bastian Schilling, Barbara Deschler-Baier · 2025 · Journal of Geriatric Oncology
  13. The problem with one-size-fits-all medicine: biological sex and the aging immune system
    Baker, Clayton, Ansere, Victor A., Sanqui, Cossette I., Benayoun, Bérénice A. · 2026 · PLOS Biology
  14. Safety and efficacy of minimally invasive gastrectomy for older patients with gastric cancer after neoadjuvant chemotherapy and immunotherapy: a propensity score-matched analysis
    Hao Cui, Zhen Yuan, Wenquan Liang, Bo Cao, Lin Chen, Jianxin Cui, Bo Wei · 2024 · BMC Geriatrics
  15. Multi-detector computed tomography (MDCT)–based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis
    Nisanard Pisuchpen, Sienna Durbin, Meghan J. Mooradian, Florian Johannes Fintelmann, Kerry Lynn Reynolds, Michael Lawrence Dougan, Avinash R. Kambadakone · 2021 · European Radiology
  16. Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update
    Ilias Giannakodimos, Afroditi Ziogou, Alexios Giannakodimos, Konstantinos Tzelepis, Zisis Kratiras, Evangelos Fragkiadis, Ioannis Zachos, Vassilios Tzortzis, Michael Chrisofos, Nikolaos Charalampakis · 2025 · Immunotherapy
  17. CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?
    José Carlos Benítez, Jordi Remón, Benjamin Besse · 2019 · Translational Lung Cancer Research
  18. Immunotherapy in Older Patients with Advanced Melanoma: A Review of the Current Evidence
    Tiffany Foo, Gonzalo Tapia Rico, Rachel Roberts‐Thomson · 2020 · Drugs & Aging
  19. Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
    Matthew D. Biniakewitz, Mary Kate Kasler, Kristen L. Fessele · 2021 · Asia-Pacific Journal of Oncology Nursing
  20. Narrative review of immunotherapy and radiation therapy in elderly patients
    Brittney Chau, Jonnby S. LaGuardia, Caressa Hui, Linda Ye, Yan Xing, Erminia Massarelli, Arya Amini · 2021 · Translational Cancer Research
  21. Multimodality Treatment with Radiotherapy and Immunotherapy in Older Adults: Rationale, Evolving Data, and Current Recommendations
    Elizabeth Germino, Ameish Govindarajan, Mina S. Sedrak, Daneng Li, Arya Amini · 2022 · Seminars in Radiation Oncology
  22. How to report and discuss subgroup analyses in clinical practice guidelines? Evaluation procedure of the clinical and statistical relevancy
    Kiichiro Ninomiya, Satoru Miura, Yuko Oya, Tomohiro Sakamoto, Kentaro Tanaka, Shunsuke Teraoka, Masahiro Morise, Satoshi Morita · 2025 · International Journal of Clinical Oncology
  23. A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
    Yingjie Qiu, Han Yan, Beibei Guo · 2026 · Statistics in Medicine
  24. Conquering aging-related immunosenescence and tumor immune escape
    Shanshan Zhang, Bo Yang, Mingyi Xu, 邴英, Jiwang Zhang, Y. Lynn Wang, Chaohui Zheng, Gang Zhang, Leisheng Zhang · 2026 · Frontiers in Immunology
  25. Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers
    Sambit Kumar Mohanty, Sourav Kumar Mishra, Mahul B. Amin, Abbas Agaimy, Florian Siegfried Fuchs · 2023 · Advances in Anatomic Pathology
  26. Cancer Among the Elderly
    Satheesan Balasubramanian, Geetha Muttath, Rohit Karan · 2023 · Springer eBooks
  27. Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma
    Khalil Choucair, Andrew Elliott, Matthew James Oberley, Phillip Walker, April K.S. Salama, Azhar Saeed, Hirva Mansurali Mamdani, Dipesh Uprety, Wafik S. El‐Deiry, Himisha Beltran et al. · 2025 · BMJ Oncology
  28. Integrating cuproptosis and immunosenescence: A novel therapeutic strategy in cancer treatment
    Ali Ahmadizad Firouzjaei, Seyed Hamid Aghaee‐Bakhtiari · 2025 · Biochemistry and Biophysics Reports
  29. Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies
    Saar I. Gill · 2016 · Current Hematologic Malignancy Reports
  30. Inhibiteurs de “check point”, quelles perspectives pour les patients âgés ?
    Thierry Landre, Fatima Karaoud, Chérifa Taleb · 2017 · Soins Gérontologie
  31. Données d’efficacité et de toxicité des immunothérapies anti cancéreuses chez le sujet âgé – 5e journée de pharmacologie des anti-tumoraux
    Hortense de Saint Basile, Caroline Poisson, Jennifer Arrondeau, Pascaline Boudou, François Goldwasser, Éric Tartour, Éléonore De Guillebon · 2018 · Bulletin du Cancer
  32. Expanding Therapeutic Options for Older Adults: Case‐Based Updates in Breast and Lung Cancer
    Allison M. Magnuson, Rawad Elias, Thuy T. Koll · 2019 · Journal of the American Geriatrics Society
  33. PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
    Xiangjiao Meng, Yu Chen, Ligang Xing, Xinchao Liu, Kaikai Zhao, Liyang Jiang, Li Zhang, Caicun Zhou, Jinming Yu · 2022 · BMJ Open Respiratory Research
  34. A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer
    Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Sato et al. · 2023 · Thoracic Cancer
  35. Bladder Cancer in Older Adults
    N. Talji, Nicolas Mottet · 2020 · Springer eBooks
  36. Expanding the PD-L1 Paradigm: A Comprehensive Systematic Review and Meta-Analysis of Scoring Systems and Additional Biomarkers Influencing Immune Checkpoint Inhibitor Outcomes in Breast Cancer
    Shuangwei Mo, Yuxian Wang, Yaoling Wang, Xinhai Chen, Hongyi Zhu, Zhengrong Zou, Weikai Xiao · 2024 · Cancer Control
  37. Age and Clinical Outcomes of Immune Checkpoint Inhibitor Toxicities in Portugal: A Decade of Pharmacovigilance
    Tiago Pina-Cabral, José Pereira, João Paulo-Fernandes, Márcia Silva, Mário Fontes-Sousa, Mariana Anacleto, Soraia Lobo-Martins, Ana Mirco, Helena Miranda, Ana Martins et al. · 2025 · Cancers
  38. Urgent need to define Pretreatment predictors of immune check point inhibitors related endocrinopathies: A case report and review of literature
    Vishal Sehgal, Richard Dale Childress · 2017 · Journal of Translational Internal Medicine
  39. Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review
    Rui An, Feng Hua Zhao, Liqian Wang, Jikang Shan, Xianjun Wang · 2021 · BMJ Open
  40. The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis
    Min Hou, Haiyan Xing, Shuangshuang He, Xue Yang, Dan Peng, Yang Li, Qing Hua Zhang, Pan Zhang, Yunqi Ma, Juan Li et al. · 2022 · Journal of Oncology
  41. Immune Checkpoint inhibitor Therapy in Various Cancers
    Yining Sun, Nan Wang, Nuo Zhang · 2022 · Highlights in Science Engineering and Technology
  42. Analysis of Hepatic Adverse Event in Patients Treated with Immune Checkpoint Inhibitor
    Ji Hyeon Park, Jung Hyun Kim, Eun Young Jeon, Hu Kyoung Lee, Myung Sook Min · 2022 · Journal of Korean Society of Health-System Pharmacists
  43. Predicting the efficacy of immune checkpoint inhibitors monotherapy in advanced non-small cell lung cancer: a machine learning method based on multidimensional data
    Na Liu, Bilin Liang, Lu Lu, Bing-Qian Zhang, Jingjing Sun, Jiantao Yang, Jie Xu, Zhengbo Song, Lei Shi · 2023 · Neoplasma
  44. Immunotherapy: should we worry about immunosenescence?
    A. Özkan, Nienke Aafke de Glas, Johanneke E. A. Portielje · 2024 · Ageing and Cancer Research & Treatment
  45. To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition
    Stijn De Keukeleire, Tijl Vermassen, Gert De Schoenmakere, Vibeke Krüse, Karim Y. Vermaelen, Sylvie Rottey · 2019 · Acta Clinica Belgica
  46. Impact of age‐related T‐cell dynamics on the identification of biomarkers predictive of immunotherapy discontinuation: A prospective cohort study
    Jason E. Galloway, Andrea M. Holderbaum, Namrata Arya, Suohui Zhang, Michael S. Bodnar, Ruthann Norman, William Edgar Carson, Lianbo Yu, Kari Lynn Kendra, Christin Elizabeth Burd · 2020 · Aging and Cancer
  47. Radiotherapy and Systemic Anti-Cancer Treatment in Older Adults with Cancer and Frailty
    Anita O’Donovan, Capucine Baldini, Nicolò Matteo Luca Battisti · 2022 · Springer eBooks
  48. Postoperative recurrence factors in patients with pT3N0M0 clear cell renal cell carcinoma, called M0 intermediate-high-risk group of the KEYNOTE 564 trial
    Hirohito Naito, Homare Okazoe, Ryou Ishikawa, Tomoko Honda, Yu Osaki, Yohei Abe, Yoichiro Tohi, Yuki Matsuoka, Takuma Kato, Rikiya Taoka et al. · 2023 · Research Square
  49. Lungenkarzinom beim alten und geriatrischen Patienten
    Martin B. Steins, Jonas Kuon, Michael Thomas · 2018 · Springer eBooks
  50. Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie
    Henning Schulze‐Bergkamen · 2018 · Springer eBooks
  51. Editorial: Teaching old CAR-T cells new tricks
    Lindsey M. Kuehm, Ryan M. Teague · 2017 · Journal of Leukocyte Biology
  52. Cancer in Older Adults
    William Harrell Ward, Efrat Dotan, Joshua E. Meyer, Nestor F. Esnaola · 2018 · Springer eBooks
  53. Immunological Methods and the Concept of Inflammaging in the Study of Human Aging
    Tamàs Fülöp, Graham Pawelec, Jacek Maciej Witkowski, Alan Arthur Cohen, Carl F Fortin, Aurélie Y. Le Page, Hugo Garneau, Gilles Dupuis, Anis Larbi · 2018 · Elsevier eBooks
  54. Bladder Cancer in Older Adults
    N. Talji, Nicolas Mottet · 2018 · Springer eBooks
  55. An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function
    Manami Sazuka, Yoko Murano, Kazufumi Takada, Keisuke Nonaka, Hirokazu Yamada, Hiroshi Yamamoto · 2018 · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics
  56. Cancer in Older Adults
    Hüseyin Salih Semiz · 2019 · Elsevier eBooks
  57. Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma
    Tiffany Foo, Gonzalo Tapia Rico, Michael Paul Brown · 2020 · BMJ Case Reports
  58. Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
    Mustafa Abdo · 2021
  59. Patient Age Associates With Tumor-Infiltrating Lymphocytes Density In Breast Cancer
    Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira · 2021 · Research Square
  60. Immune and targeted therapy for cancer: time to rethink restrictions for the treatment of the elderly and frail
    Juliana Rodrigues Beal, Gustavo Schvartsman, Rodrigo Ramella Munhoz, Theodora Karnakis, Rafael Aliosha Kaliks · 2021 · Brazilian Journal of Oncology
  61. Immunotherapy in elderly patients
    Marina A. Lyadova, Vladimir Konstantinovich Lyadov · 2021 · Meditsinskiy sovet = Medical Council
  62. Immunotherapy
    Lore Decoster, Sandrine Aspeslagh · 2021 · Springer eBooks
  63. Cancer in Older Adults
    William Harrell Ward, Efrat Dotan, Joshua E. Meyer, Nestor F. Esnaola · 2020 · Springer eBooks
  64. Patient Age Associates with Tumor-Infiltrating Lymphocytes Density in Breast Cancer
    Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira · 2021 · Research Square
  65. Lungenkarzinom beim alten und geriatrischen Patienten
    Martin B. Steins, Jonas Kuon, Michael Thomas · 2017 · Springer eBooks
  66. Immunotherapy
    Lore Decoster, Sandrine Aspeslagh · 2020 · Springer eBooks
  67. Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie
    Henning Schulze‐Bergkamen · 2016 · Springer eBooks
  68. Patient Age Associates with Tumor-Infiltrating Lymphocytes Density in Breast Cancer
    Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira · 2021 · Research Square
  69. Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0
    Aknar Calabrich, Alberto Julius Alves Wainstein, Andréia Cristina de Melo, Antonio Carlos Buzaid, Artur Katz, Carlos Gil Ferreira, Carlos Henrique dos Anjos, Clarissa Serodio da Rocha Baldotto, Clarissa Maria de Cerqueira Mathias, Elimar Elias Gomes et al. · 2022 · Brazilian Journal of Oncology
  70. Immunotherapy in gynecologic malignancies
    Malte Renz, Oliver Dorigo · 2022 · Elsevier eBooks
  71. Analysis on immune checkpoint inhibitors for elder patients: benefits and costs relative to chemotherapy
    Shengdi Sun · 2023 · International Conference on Modern Medicine and Global Health (ICMMGH)
  72. Mechanisms of resistance to immunotherapy
    Bernadette Blauensteiner, Theresa Lentner, Verónica Moreno‐Viedma · 2024 · Elsevier eBooks
  73. Comparison of monotherapy and combination therapy for older patients with advanced biliary tract cancer: a retrospective study
    Ritsuko Oishi, Satoshi Kobayashi, Shuhei Nagashima, Taito Fukushima, Shun Tezuka, Manabu Morimoto, Makoto Ueno, Shin Maeda · 2025 · BMC Cancer
  74. Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma
    Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto, Shinsuke Mizoguchi, Takayuki Nakayama, Hironori Fukuda, Hiroaki Shimmura, Yasunobu Hashimoto, Kazuhiko Yoshida, Junpei Iizuka et al. · 2025 · Geriatrics and gerontology international/Geriatrics & gerontology international
  75. Cancer Among the Elderly
    Satheesan Balasubramanian, Geetha Muttath, Rohit Karan · 2025 · Springer eBooks
  76. Altersdiskriminierung in institutionellen Kontexten
    Maria Wirth, Klaus Rothermund · 2025 · Springer eBooks
  77. Additional file 6 of Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
    Takada, Koji, Kashiwagi, Shinichiro, Asano, Yuka, Goto, Wataru, Morisaki, Tamami, Shibutani, Masatsune, Tanaka, Hiroaki, Kosei Hirakawa, Ohira, Masaichi · 2022 · Figshare
  78. Additional file 4 of Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
    Takada, Koji, Kashiwagi, Shinichiro, Asano, Yuka, Goto, Wataru, Morisaki, Tamami, Shibutani, Masatsune, Tanaka, Hiroaki, Kosei Hirakawa, Ohira, Masaichi · 2022 · Figshare
  79. Additional file 1 of CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC)
    Liu, Shiyi, Wang, Feiyan, Tan, Wei, Zhang, Li, Fangfang Dai, Wang, Yanqing, Fan, Yaqi, Yuan, Mengqin, Yang, Dongyong, Zheng, Yajing et al. · 2020 · Figshare
  80. Additional file 2 of Safety and efficacy of minimally invasive gastrectomy for older patients with gastric cancer after neoadjuvant chemotherapy and immunotherapy: a propensity score-matched analysis
    Hao Cui, Yuan, Zhen, Wenquan Liang, Bo Cao, Lin Chen, Cui, Jianxin, Wei, Bo · 2024 · Figshare
  81. Additional file 1 of Safety and efficacy of minimally invasive gastrectomy for older patients with gastric cancer after neoadjuvant chemotherapy and immunotherapy: a propensity score-matched analysis
    Hao Cui, Yuan, Zhen, Wenquan Liang, Bo Cao, Lin Chen, Cui, Jianxin, Wei, Bo · 2024 · Figshare
  82. Additional file 3 of Safety and efficacy of minimally invasive gastrectomy for older patients with gastric cancer after neoadjuvant chemotherapy and immunotherapy: a propensity score-matched analysis
    Hao Cui, Yuan, Zhen, Wenquan Liang, Bo Cao, Lin Chen, Cui, Jianxin, Wei, Bo · 2024 · Figshare
  83. Additional file 5 of Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
    Takada, Koji, Kashiwagi, Shinichiro, Asano, Yuka, Wataru Goto, Morisaki, Tamami, Shibutani, Masatsune, Tanaka, Hiroaki, Kosei Hirakawa, Ohira, Masaichi · 2022 · Figshare
  84. Additional file 1 of NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice
    Junlei Hou, Xie, Shuanglong, Jianbao Gao, Tao Jiang, Enjian Zhu, Xuezhi Yang, Jin, Zheng, Long, Haixia, Zhang, Anmei, Fei Yang et al. · 2024 · Figshare
  85. Survival and toxicity profile of elderly melanoma patients treated with immune checkpoint inhibitors: a retrospective study from a tertiary care center
    Mónica Pozuelo‐Ruiz, Blanca de Unamuno‐Bustos, Fernando Navarro‐Blanco, Rodolfo David Palacios‐Diaz, Rafael Botella Estrada · 2026 · Melanoma Research
  86. IL-6 and Immunosenescence in the Current Research on Immunotherapy for Elderly Lung Cancer Patients
    思岩 李 · 2026 · Advances in Clinical Medicine
  87. Efficacy and safety of immunotherapy in elderly patients with advanced non-small cell lung cancer: a real-world study stratified by age
    Yi Dong, Mei-Cen Liu, Yunye Mao, Yi-Heng Lu, An Wang, X X Zhou, Yin-Min Ji, Shu-Yan Xiao, Ya-hui Lv, Tao Li et al. · 2026 · BMC Geriatrics
  88. Treatment Option for Deficient Mismatch Repair (dMMR) and Proficient Mismatch Repair (pMMR) in Endometrial Cancer
    I Gde Sastra Winata, Jessica Nathalia, Prayascita Mahendrata · 2026 · Journal of South Asian Federation of Obstetrics and Gynaecology
  89. Differential Toxicity of Immune Checkpoint Inhibitors in Older Adults: A Large-Scale, Propensity Score-Matched Real-World Analysis
    Muhammad A. Awidi, Muntaser Al Zyoud, Noor S. Bader, AHMAD AL-ALWAN, Muhammad Junaid Tariq · 2026 · Cancer Investigation
  90. Letter to the Editor: Programmed death-1/programmed death-ligand 1 inhibitors in the treatment of elderly patients with advanced pancreatic cancer
    Yan Feng, Hai-Wei Yu, Ke Xu · 2026 · World Journal of Gastrointestinal Oncology
  91. Renal Cell Carcinoma in the Geriatric Population: Toward a Frailty-Adapted Therapeutic Paradigm
    Cemile Özsürekçi, Ufuk Yazar, Yusuf Açıkgöz · 2026 · Journal of Clinical Medicine
  92. Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy
    Hongjiao Wu, Zhenbang Yang, Hongmei Zhang, Ye Jin, Shanshan Ji, Zhi Zhang, Guogui Sun, Xuemei Zhang · 2026 · Critical Reviews in Oncology/Hematology